Launching a UK HRT (hormone replacement therapy) clinic online in 2026 requires three things: clinical compliance with NICE NG23 on menopause and broader prescribing guidance, secure handling of patches, gels, tablets, and vaginal preparations including stability-sensitive SKUs, and a patient pathway built around shared decision-making and ongoing review. The category is high-demand, well-evidenced, and operationally established. This piece is the launch brief for founders entering it.
Why HRT online is a defensible category — evidence, demand, NHS gap
HRT for menopause has a strong evidence base and clear NICE-aligned prescribing pathway. NHS HRT-PPC (Prescription Prepayment Certificate) covers HRT at reduced cost on the NHS, but availability and waiting times have driven significant private demand. Private online HRT has scaled steadily across 2023-2026 because the patient need is real, the clinical pathway is well-defined, and remote delivery suits the medication review cadence.
Clinical eligibility and shared decision-making
HRT prescribing follows NICE NG23 and clinician judgement on benefit-risk. Eligibility considerations include menopausal status, symptoms, contraindications (history of breast cancer, certain thromboembolic events, undiagnosed bleeding), and patient preference. The consultation must support shared decision-making — patients choosing route (oestrogen plus progesterone vs combined patches vs gels), formulation, and the cadence of ongoing monitoring.
The product mix — patches, gels, tablets, vaginal preparations
HRT product range in the UK spans oestrogen patches, gels, sprays, oral tablets, vaginal preparations, and progesterone (oral, IUS). Some are room-temperature; some have stability windows that require careful supply chain handling. Brands launching narrow (one or two product lines) reach operational stability faster than brands launching the full catalogue at once.
Patient pathway — initial consultation, titration, six-monthly review
HRT patient pathways follow: initial consultation with full menopause and medical history, prescribing decision and patient choice of preparation, ongoing review at 3 months for tolerability and titration, then six-monthly or annual review for continuation. Routine monitoring (BP, weight, breast awareness) should be part of the structured review. A pathway that auto-refills without review is not defensible at inspection.
Regulatory posture — same regulators, HRT-specific watch points
HRT prescribing in the UK sits under standard regulators (GPhC, MHRA, CQC, ICO). Specific HRT watch points: ASA enforcement on menopause and HRT advertising (no comparative efficacy claims, no testimonials for POMs), MHRA position on bioidentical and compounded HRT (significantly more constrained than licensed HRT), and Yellow Card reporting for adverse reactions including thromboembolic events and abnormal bleeding.
How PExpo supports HRT brand launches
PExpo's brand model includes the clinical workflow, UK prescriber network, dispensing infrastructure for the HRT product range (including handling for stability-sensitive SKUs), and the integrations a patient pathway needs. The brand operates patient-facing; PExpo operates the regulated layers. See our brand model page for the full scope, or our clinic model page if you are a clinic adding HRT to an existing offering.
A pathway that auto-refills HRT without scheduled review is not defensible at inspection. Build the six-monthly review into the patient flow, not as an afterthought.
Brands launching narrow reach operational stability faster than brands launching full catalogue. HRT has the same pattern — one or two formulations first.
Launching a UK HRT clinic online in 2026 is a defensible build with strong evidence base and durable patient demand. The operators who follow NICE alignment, design proper shared-decision-making consultations, and build the six-monthly review into the patient pathway compound. The ones who treat HRT as a refill product remediate later. See our brand model page for the white-label launch route, or our clinic model page for HRT inside an existing clinic.
Frequently asked questions
What do I need to launch a UK HRT clinic online?
A clinical workflow aligned with NICE NG23 and shared decision-making, prescribing capability under MHRA-aligned medicines handling, a GPhC-registered dispensing pharmacy (or partner), a structured patient pathway with six-monthly review, and CQC registration in England. PExpo's brand model includes the clinical, prescribing, and dispensing layers as a managed stack.
Can I prescribe HRT remotely in the UK?
Yes — HRT is well-suited to remote prescribing when the clinical consultation is structured properly and follow-up review is built into the pathway. The same standards apply as in-person prescribing under NICE and GMC/GPhC standards.
Does PExpo handle the HRT product range?
Yes — PExpo dispenses across the licensed HRT product range including formulations that require careful supply chain handling. See our brand model page for the full SKU breadth.
What's the difference between licensed HRT and bioidentical or compounded HRT?
Licensed HRT is MHRA-approved with established evidence base, manufacturing standards, and labelling. Bioidentical and compounded HRT is not MHRA-licensed and the MHRA position on its advertising and prescribing is significantly more constrained. PExpo dispenses licensed HRT only.
